Singapore markets open in 1 hour 2 minutes

Emergent BioSolutions Inc. (EBS)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
2.2900+0.1300 (+6.02%)
At close: 04:00PM EDT
2.2900 0.00 (0.00%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1600
Open2.1500
Bid2.3000 x 2200
Ask2.2800 x 4000
Day's range2.1300 - 2.3600
52-week range1.4200 - 10.8800
Volume860,990
Avg. volume3,039,045
Market cap119.975M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

    GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this

  • GlobeNewswire

    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

    Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct

  • GlobeNewswire

    Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

    As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locationsApproximately 22 million doses of NARCAN®